Chemical formula: C₁₇H₂₅NO Molecular mass: 259.387 g/mol PubChem compound: 3236
Eperisone should only be used in pregnant women or women suspected of being pregnant, if the expected therapeutic benefits are evaluated to outweigh the possible risk of treatment [The safety of eperisone in pregnant women has not been established].
It is advisable to avoid the administration of eperisone to nursing mothers. When eperisone must be used, breast feeding should be discontinued during treatment [It has been reported that eperisone is excreted in breast milk in an animal study (in rats)].
Weakness, light-headedness, sleepiness or other symptoms may occur. In the event of such symptoms, the dosage should be reduced or treatment discontinued. Patients should be cautioned against engaging in potentially hazardous activities requiring alertness, such as operating machinery or driving a car.
Adverse reactions were reported in 416 of 12,315 patients (3.38%) (At the end of the reexamination period).
Since shock and anaphylactoid reactions may occur, patients should be carefully observed. In the event of symptoms such as redness, itching, urticaria, edema of the face or other parts and dyspnea etc., treatment should be discontinued and appropriate measures taken.
Serious dermatopathy such as oculo-muco-cutaneous syndrome (Stevens-Johnson syndrome) or toxic epidermal necrolysis (Lyell syndrome) may occur. Patients should be carefully observed, treatment discontinued and appropriate measures taken, in the event of symptoms such as fever, erythema, blistering, itching, ocular congestion or stomatitis, etc.
| 5% > ≥0.1% | <0.1% | Incidence unknown | |
| Hepatic note 1) | Elevation of AST (GOT), ALT and Al-P, etc. | ||
| Renalnote 1) | Proteinuria and Elevation of BUN, etc. | ||
| Hematologicnote 1) | Anemia | ||
| Hypersensitivitynote 2) | Rash | Pruritus | erythema, exudativum, multiforme |
| Psychoneurologic | Sleepiness, insomnia, headache and numbness in the extremities | Stiffness and tremor in the extremities | |
| Gastrointestinal | Nausea/vomiting, anorexia, stomach discomfort, abdominal pain, diarrhea, constipation and thirst | Stomatitis and feeling of enlarged abdomen | |
| Urinary | Urinary retention, urinary incontinence and feeling of residual urine | ||
| General | Weakness, light-headedness and generalized fatigue | Muscle hypotonia and dizziness | |
| Others | Hot flushes | Diaphoresis and edema |
Note 1) Since these symptoms may occur, patients should be carefully observed. In the event of such abnormalities, treatment should be discontinued and appropriate measures taken.
Note 2) In the event of such symptoms, treatment should be discontinued.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
